PMID- 30065812
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2040-6223 (Print)
IS  - 2040-6231 (Electronic)
IS  - 2040-6223 (Linking)
VI  - 9
IP  - 8
DP  - 2018 Aug
TI  - Safety and tolerability of adalimumab for the treatment of psoriasis: a review 
      summarizing 15 years of real-life experience.
PG  - 147-158
LID - 10.1177/2040622318772705 [doi]
AB  - Biologic therapies like adalimumab are the gold standard for psoriasis treatment 
      with efficacy and safety profiles allowing for long-term treatment. However, 
      adalimumab cannot be used in all patients and may cause adverse drug reactions. 
      This study reviews conditions that might limit the use of adalimumab under 
      real-life conditions. Local injection site reactions affect 12-37% of patients 
      but rarely require specific therapy. Dermatological adverse events (AEs) include 
      the paradoxical psoriasis and tend to respond to adequate therapy without 
      adalimumab discontinuation. Adalimumab increases the risk for infections; latent 
      chronic infections like tuberculosis or hepatitis B/C impose the highest risk for 
      serious AEs. However, administration of adalimumab may still be possible under 
      appropriate monitoring or prophylactic therapy. Some studies indicate an 
      increased risk of malignancies in patients with psoriasis exposed to adalimumab. 
      Here, the causal relationship is unclear since both psoriasis and some first-line 
      therapies increase the risk of malignancies. Depression frequently coincides with 
      psoriasis and may respond to adalimumab as well. Cardiovascular diseases are 
      contraindications for adalimumab, but evidence suggests that adalimumab may still 
      be a treatment option. Overall AE rates range from 245 to 399 per 100 patient 
      years (serious AEs: 6-23; death: 1-2). Thus, adalimumab is slightly less safe 
      than ustekinumab and infliximab but exhibits superior effectiveness and drug 
      survival. Adalimumab is safe for pregnant women during the first trimester, for 
      children up to 4 years and for the elderly. Thus, in spite of several conditions 
      that require specific attention, the favourable safety and tolerability of 
      adalimumab for the treatment of psoriasis is confirmed.
FAU - Sator, Paul
AU  - Sator P
AD  - Department for Dermatology, Krankenhaus Hietzing, Austria.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180522
PL  - United States
TA  - Ther Adv Chronic Dis
JT  - Therapeutic advances in chronic disease
JID - 101532140
PMC - PMC6052502
OTO - NOTNLM
OT  - adalimumab
OT  - adverse drug reaction
OT  - antidrug antibodies
OT  - biologica
OT  - local injection site reaction
OT  - long-term safety
OT  - opportunistic infection
OT  - protected patient groups
OT  - safety profile
OT  - special patient populations
OT  - tumour necrosis factor alpha
COIS- Conflict of interest statement: The author(s) declared no potential conflicts of 
      interest with respect to the research, authorship, and/or publication of this 
      article.
EDAT- 2018/08/02 06:00
MHDA- 2018/08/02 06:01
PMCR- 2018/08/01
CRDT- 2018/08/02 06:00
PHST- 2017/12/18 00:00 [received]
PHST- 2018/03/23 00:00 [accepted]
PHST- 2018/08/02 06:00 [entrez]
PHST- 2018/08/02 06:00 [pubmed]
PHST- 2018/08/02 06:01 [medline]
PHST- 2018/08/01 00:00 [pmc-release]
AID - 10.1177_2040622318772705 [pii]
AID - 10.1177/2040622318772705 [doi]
PST - ppublish
SO  - Ther Adv Chronic Dis. 2018 Aug;9(8):147-158. doi: 10.1177/2040622318772705. Epub 
      2018 May 22.